To Serve Patients

SummarySUMMARY

Amgen Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology. The company markets human therapeutic products primarily in the areas of supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and Epogen that stimulate the production of red blood cells to treat anemia; Neulasta and Neupogen, which selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections; and Enbrel that blocks the biologic activity of tumor necrosis factor by inhibiting TNF, a substance induced in response to inflammatory and immunological responses, such as rheumatoid arthritis and psoriasis. The company has a joint venture with Kirin Holdings Company, Limited to manufacture and market darbepoetin alfa; a co-promotion agreement with Wyeth for marketing and selling of Enbrel;and Johnson & Johnson to commerci

BrandFINANCIAL OVERVIEW

Industry Health
Revenues $ 20,000
Media spending $ 145
Income -
Employees 17,900

SummaryCOMPETITIVE BENCHMARK

AMGEN CONSUMER IN US

Updated on: Dec. 15, 2016


:) HELP